Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas

Clinical Neurology and Neurosurgery

Volumn 111, Issue 9, 2009, Pages 748-751

  Rhee, Deok Joo ^a   Kong, Doo Sik ^a   Kim, Won Seog ^a   Park, Kwon Byong ^a   Lee, Jung Il ^a   Suh, Yeon Lim ^a   Song, Sang Young ^a   Kim, Sung Tae ^b   Lim, Do Hoon ^a   Park, Kwan ^a   Kim, Jong Hyun ^a   Nam, Do Hyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Adjuvant chemotherapy; Glioblastoma; Temozolomide

Indexed keywords

LOMUSTINE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; NITROSOUREA COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 70349549904     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2009.07.014     Document Type: Article

References (18)

1. Mineo J.F., Quintin-Roue I., Lucas B., Buburusan V., and Besson G. Glioblastomas: clinical study and search for prognostic factors. Neurochirurgie 48 (2002) 500-509
2. Mineo J.F., Bordron A., Baroncini M., Ramirez C., Maurage C.A., Blond S., et al. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir (Wien) 149 (2007) 245-253
3. Ushio Y., Kochi M., Hamada J., Kai Y., and Nakamura H. Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma. Neurol Med Chir (Tokyo) 45 (2005) 454-460 [discussion 460-451]
4. Fine H.A., Dear K.B., Loeffler J.S., Black P.M., and Canellos G.P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 (1993) 2585-2597
5. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
6. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19 (2001) 509-518
7. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
8. Buckner J.C., Ballman K.V., Michalak J.C., Burton G.V., Cascino T.L., Schomberg P.J., et al. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24 (2006) 3871-3879
9. Prados M.D., Seiferheld W., Sandler H.M., Buckner J.C., Phillips T., Schultz C., et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58 (2004) 1147-1152
10. Grossman S.A., and Batara J.F. Current management of glioblastoma multiforme. Semin Oncol 31 (2004) 635-644
11. Norden A.D., and Wen P.Y. Glioma therapy in adults. Neurologist 12 (2006) 279-292
12. Rabbani G., Benzil D., Wallam M.N., Chen B., Hoang A., Kancherla R., et al. Combination therapy with thalidomide, temozolomide and tamoxifen improves quality of life in patients with malignant astrocytomas. Anticancer Res 27 (2007) 2729-2736
13. Riva M., Imbesi F., Beghi E., Galli C., Citterio A., Trapani P., et al. Temozolomide and thalidomide in the treatment of glioblastoma multiforme. Anticancer Res 27 (2007) 1067-1071
14. Zustovich F., Cartei G., Ceravolo R., Zovato S., Della Puppa A., Pastorelli D., et al. A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors. Anticancer Res 27 (2007) 1019-1024
15. Huang J., Moore J., Soffer S., Kim E., Rowe D., Manley C.A., et al. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg 36 (2001) 357-361
16. Browder T., Butterfield C.E., Kraling B.M., Shi B., Marshall B., O'Reilly M.S., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886
17. Meckling S., Dold O., Forsyth P.A., Brasher P., and Hagen N.A. Malignant supratentorial glioma in the elderly: is radiotherapy useful?. Neurology 47 (1996) 901-905
18. Chinot O.L., Barrie M., Frauger E., Dufour H., Figarella-Branger D., Palmari J., et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100 (2004) 2208-2214